Based on the MMSE score, biochemical analyses and clinical picture, we chose patients with not very advanced AD because we aimed to check if the concentrations of selected synaptic proteins may reflect the early synaptic pathology and there is a relationship with amyloid and tau biomarkers in the early phase of full-blown disease. Here, MAPT is linked to Alzheimer disease.